Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy

Pediatric Transplantation

Volumn 7, Issue 5, 2003, Pages 404-407

  Venzke, Andrea ^a   Ganschow, R ^a   Grabhorn, E ^a   Rogiers, X ^a   Burdelski, M ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

B cells; Basiliximab; Children; Liver tansplantation; Posttransplant lymphoproliferative disease

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BILE DUCT ATRESIA; CANCER CHEMOTHERAPY; CASE REPORT; CHOLESTASIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTESTINE LYMPHOMA; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD; SMALL INTESTINE PERFORATION; T LYMPHOCYTE ACTIVATION; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; LYMPHOMA, B-CELL; MALE; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0142022910     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2003.00062.x     Document Type: Article

References (19)

1. GANSCHOW R, BROERING DC, STUERENBURG I, ROGIERS X, HELLWEGE HH, BURDELSKI M. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplantation 2000: 7: 8-10.
2. zKAHAN BD, RAJAGOPALAN PR, HALL M. Reduction of the occurence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantion 1999: 67: 276-280.
3. NASHAN B, SCHLITT HJ, SCHWINZER R, RINGE B, KUSE E, TUSCH G, WONIGEIT K, PICHMAYR R. Immunoprophylaxis with a monoclonal anti-IL-2-receptor antibody in liver transplant patients. Transplantation 1996: 61: 546-551.
4. SEIDEN MV, SKLAR J. Molecular genetic analysis of post-transplant lymphoproliferative disease. Hematol Oncol Cli North Am 1993: 7: 447-451.
5. FALCO DA, NEPOMUCENO RR, KRAMS SM, et al. Identification of Epstein-Barr-virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002: 74: 501-507.
6. NEWELL KA, ALSONO EM, WHITINGTON PF, et al. Postttransplant lymphoproliferative disease in pediatiric liver transplantation. Interplay between Epstein-Barr virus infection and immunosuppression. Transplantaion 1996: 62: 370-375.
7. UPTON A, HEBERT D, MOORE D, DROR Y, WASFY S. Canadian PTLD Survey Group. Epstein-Barr virus-related disease in solid organ transplant recipients, 1988-97: A Canadian multicenter experience. Pediatr Transplant 2001: 5: 198-203.
8. MOLMENTI EP, NAGATA DE, RIDEN JS, et al. Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population. Am J Transplant 2001: 1: 356-361.
9. YOUNES BS, MCDIARIMID SV, MARTIN MG, VARGAS JH, GROSS JA, BUSUTTIL RW, AMENT ME. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000: 70: 94-99.
10. COLLINS MH, MONTONE KT, LEAHEY AM, HODINKA RL, SALHANY KE, KRAMER DL, DENG C, TOMASEWSKI JE. Post-transplant lymphoproliferative disease in children. Pediatr Transplant 2001: 5: 250-257.
11. NASHAN B, MOORE R, AMLOT P, SCHMIDT A, ABEYWICKRAMA A. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997: 350: 1193-1198.
12. KAHAN BD, RAJAGOPALAN PR, HALL M. Transplantation 1999: 67: 276-284.
13. STARZL TE, NALESNIK MA, PORTER KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984: i: 583-587.
14. GREEN M, MICHAELS MG, WEBBER SA, ROWE D, REYES J. The managment of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 1999: 3: 271-281.
15. NEWELL KA, ALONSO EM, WHITINGTON PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996: 62: 370-375.
16. CACCIARELLI TV, GREEN M, JAFFER R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus therapy. Transplantation 1998: 66: 1047-1052.
17. MALATACK JG, GARTNER A, URBACH, et al. Orthotopic liver transplantation, Epstein-Barr virus, Cyclosporine and lymphoproliferative disease. J Pediat 1991: 118: 667-675.
18. HANTO DW, FRIZZERA G, GAJL-PECZASKA KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. N Engl J Med 1982: 306: 913-918.
19. SERINET MO, JAQUEMIN E, HABES D, DEBRAY D, et al. Anti-CD20 monoclonal antibody (Rituximab) treatment fo Epstein-Barr virus associated B cell lymphoproliferative disease in pediatric liver transplant recipients. J Ped Gastent A Nutr 2002: 34: 389-393.